Year8
[Chinese name]< .
Tarceva
[English name of the product]
[Manufacturer]
Indian Pharmaceutical Factory
[Indications]< br/> rFor the third-line treatment of locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens.
[Chemical Composition]
Each tablet contains erlotinib (in the form of erlotinib hydrochloride).
[Pharmacological Action]
The anti-tumor mechanism of r is mainly to inhibit the intracellular
[Drug Interactions]
[Adverse Reactions]
The most common adverse reactions are rash and diarrhea, the incidence rates of rash and diarrhea are % and % respectively, and the median occurrence of rash Time is days, and the median onset time of diarrhea is days. Adverse reactions with an incidence rate greater than % include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain. Pulmonary Toxicity: There are rare reports of severe interstitial lung disease (), even leading to death, in patients treated with r or other solid tumors. In randomized controlled studies, the incidence rate was .% and was the same in the r treatment and placebo groups. Reported include: pneumonia, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory stress syndrome, and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiation therapy, existing parenchymal lung disease, lung metastasis or lung infection. When there are new and unexplained pulmonary symptoms, such as dyspnea, cough, fever, etc., examination and evaluation are required. Once diagnosed, use of r should be stopped and appropriate treatment should be taken. Hepatotoxicity: Treatment can cause asymptomatic increases in liver transaminase. Therefore, liver function should be reviewed regularly during treatment, including: transaminase, bilirubin, alkaline
【Contraindications】
It is prohibited for those allergic to this product and its ingredients.
[Product Specifications]
[Usage and Dosage]
This product must be used under the guidance of doctors with experience in the use of such drugs, and only in the National Oncology Drug Clinical Trial Base or Used by Class IIIA hospitals. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is/day, taken at least one hour before or one hour after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression.
【Storage Method】
Store at ℃, temperatures between ℃ and ℃ are also acceptable.
[Precautions]
This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in national oncology drug clinical trial bases or tertiary A hospitals
WhatsApp
